Homepage Top Section1

The medicine is said to be the first and only specific interleukin-23 (IL-23) inhibitor approved for treating moderately to severely active CD in adults. The approval follows the

Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty

PreHevbri is said to be the only approved 3-antigen hepatitis B vaccine for adults in the UK. It comprises the three hepatitis B surface antigens, S, pre-S1, and

The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for

To be marketed under the proprietary name fylnetra, pegfilgrastim-pbbk was developed in collaboration with Kashiv Biosciences. Fylnetra is used for the treatment of neutropenia, a condition that occurs

Biliary tract cancer, which is also called as cholangiocarcinoma, is an extremely rare and hard to treat cancer. It impacts more than 2,000 people in the UK annually

This round was led by founding investors Syncona and Mass General Brigham Ventures. With this new funding round, SwanBio has so far raised $133m. SwanBio chair and chief

Statera Biopharma president and CEO Michael K Handley said: “The strategic partnership with Lay Sciences has the potential to produce near term revenue. “The agreement allows Statera the

This marketing authorisation is applicable for use of Kapruvia in all member states of the European Union besides Iceland, Liechtenstein and Norway. The approval comes after the US